Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation using briquilimab-based conditioning in participants with GATA2 deficienc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gata2 Deficiency
• Immunodeficiency

Drugs mentioned

• Briquilimab

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: GATA2, Immunodeficiency | Phase 2 | Status: ACTIVE_NOT_RECRUITING